Abstract Number: 377 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Stroke In Patients With Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of stroke. This event is associated with considerable sequelae and might result in death or…Abstract Number: 378 • 2013 ACR/ARHP Annual Meeting
HBV Reactivation and Consequent Hepatitis In Rheumatoid Arthritis Patients With Different HBV Carring State: A Clinical Observation Follow-Up
Background/Purpose: Approximate 7.2% Chinese were infected with hepatitis B virus (HBV), and the prevalence of concurrent HBV carriers in Chinese rheumatoid arthritis (RA) patients was…Abstract Number: 379 • 2013 ACR/ARHP Annual Meeting
Osteoporotic Fracture and Post-Operative Clinical and Cost Outcomes In Rheumatoid Arthritis: Results From Two UK Inception Cohorts
Background/Purpose: The risk of osteoporotic fracture is known to be high in RA. Yet less is known about RA related predictive factors for this…Abstract Number: 357 • 2013 ACR/ARHP Annual Meeting
Predictive Value Of Anti Cyclic Citrullinated Peptide and Rheumatoid Factor To The Development Of Rheumatoid Arthritis In a Cohort Of Healthy Relatives Of Patients With Rheumatoid Arthritis
Background/Purpose: Consanguineous relatives of patients with RA are at a higher risk to develop RA. It is also known that specific antibodies including CCP and…Abstract Number: 340 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics and Treatment Outcomes In Psoriasis Patients With Polyarthritis Or Oligoarthritis
Background/Purpose: Most randomized control trials (RCTs) for psoriatic arthritis (PsA) include patients with asymmetric oligoarthritis (AO) and polyarthritis (PA). There are limited data from RCTs…Abstract Number: 341 • 2013 ACR/ARHP Annual Meeting
Impact Of Persistent Minimal Disease Activity On Long-Term Outcomes In Psoriatic Arthritis: Results From 5 Years Of The Long Term Extension Of a Randomized, Placebo-Controlled, Study
Impact of persistent minimal disease activity on long-term outcomes in psoriatic arthritis: Results from 5 years of the long term extension of a randomized, placebo-controlled,…Abstract Number: 342 • 2013 ACR/ARHP Annual Meeting
TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile
Background/Purpose: Psoriatic arthritis (PsA) patients have increased cardiovascular morbidity and mortality. Altered lipid profile is an important risk factor for the development of these complications.…Abstract Number: 343 • 2013 ACR/ARHP Annual Meeting
Conventional Dmards For Psoriatic Arthritis: Data On 1351 Treatment Courses With Methotrexate, Sulfasalazine and Leflunomide
Background/Purpose: Methotrexate (MTX), sulfasalazine (SSZ) and leflunomide (LEF) are recommended treatments for PsA patients with active peripheral arthritis. In the publication of a recent negative…Abstract Number: 344 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis
Background/Purpose: Arthritis mutilans (AM), a severe form of psoriatic arthritis (PsA), is characterised clinically by digital shortening resulting from osteolysis and/or erosions. It is still…Abstract Number: 345 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity In Psoriatic Arthritis Patients: Impact Of Treatment With TNF Inhibitors In a Real-World Canadian Population
Background/Purpose: To determine the point prevalence of peri-articular manifestations (PAMs) in psoriatic arthritis (PsA) patients treated with anti-TNF in a real-world, Canadian, routine clinical practice…Abstract Number: 346 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, a More Severe Disease Than Psoriatic Arthritis? A Comparison Of Disease Activity In Patients With Psoriatic Arthritis and Rheumatoid Arthritis From The Swedish Early Psoriatic Arthritis Registry (SwePsA) and The Swedish Rheumatology Registry For Early RA (SRR)
Background/Purpose: In clinical practise patients with psoriatic arthritis (PsA) seem to have milder disease expression compared with patients having rheumatoid arthritis (RA). Studies have, however,…Abstract Number: 347 • 2013 ACR/ARHP Annual Meeting
Factors Explaining The Discrepancy Between Patient and Physician Global Assessment Of Disease Activity In Psoriatic Arthritis
Background/Purpose: Patients and physicians often perceive the extent of disease activity differently. We aimed to assess the factors contributing to the variability in scoring of…Abstract Number: 348 • 2013 ACR/ARHP Annual Meeting
Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy and…Abstract Number: 349 • 2013 ACR/ARHP Annual Meeting
Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis
Background/Purpose: There is a growing interest in bone and cartilage biomarkers that could be used predicting and assessing changes in structural damage in inflammatory arthritis.…Abstract Number: 350 • 2013 ACR/ARHP Annual Meeting
Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
Background/Purpose: Structural destruction in peripheral joints may occur over time in both PsA and RA. We previously reported that 47% of early PsA patients treated…